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Delivering glial cell line-derived neurotrophic factor (GDNF) to the brain is a potential treatment for Parkinson's
Disease (PD). Here we use an implantable encapsulated cell technology that uses modified human clonal ARPE-19
cells to deliver of GDNF to the brain. In vivo studies demonstrated sustained delivery of GDNF to the rat striatum
over 6 months. Anatomical benefits and behavioral efficacy were shown in 6-OHDA lesioned rats where nigral
dopaminergic neurons were preserved in neuroprotection studies and dopaminergic fibers were restored in
neurorecovery studies. When larger, clinical-sized devices were implanted for 3 months into the putamen of
G€ottingen minipigs, GDNF was widely distributed throughout the putamen and caudate producing a significant
upregulation of tyrosine hydroxylase immunohistochemistry. These results are the first to provide clear evidence
that implantation of encapsulated GDNF-secreting cells deliver efficacious and biologically relevant amounts of
GDNF in a sustained and targeted manner that is scalable to treat the large putamen in patients with Parkinson's
disease.91
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1121. Introduction
Parkinson's disease (PD) is a synucleinopathy characterized by pro-
gressive motor impairments secondary to the loss of striatal dopamine
and loss of dopamine-secreting neurons in the substantia nigra. Treat-
ment with glial cell line-derived neurotrophic factor (GDNF) has poten-
tial to slow or reverse the loss of dopaminergic function in PD patients.
GDNF has consistently shown anatomical and behavioral benefits in 6-
OHDA rats (Dowd et al., 2005; Grondin, Zhang, Ai, Gash, & Gerhardt,
2003; Wang et al., 2002; Zheng et al., 2005), MPTP lesioned monkeys
(Gash et al., 1996; Kordower et al., 2000; Miyoshi et al., 1997; Palfi et al.,
2002) and aged monkeys (Kordower et al., 2000). GDNF has been tested
in PD patients with encouraging but inconsistent results. The lack of
robust clinical efficacy has been suggested to be a result of poor distri-
bution of GDNF to the nigrostriatal system (Kordower et al., 1999; Lang
et al., 2006; Nutt et al., 2003; Salvatore et al., 2006; Sherer, Fiske,
Svendsen, Lang, & Langston, 2006).
Here we report on the continued development of a cell-based tech-
nology with the potential to deliver efficacious levels of GDNF, or othernc. 130 Franklin St., STE 2, Warr
hlberg).
orm 14 April 2020; Accepted 16
is an open access article under t
., Long-term, stable, targeted b
arch in Pharmacology and Drumolecules, directly to the brain (Emerich et al., 1996, 2014; Kishima
et al., 2004; Lindner et al., 1995; Lindvall & Wahlberg, 2008). In this
approach cells are engineered to secrete GDNF and are then enclosed in a
semipermeable capsule, which is then implanted directly into the brain.
The semipermeable nature of the membrane allows the cells to remain
viable and distribute GDNF to the surrounding brain while also reducing
immunological reactions to the encapsulated cells allowing cells from
allo- and xenogeneic sources to be used. Building off previous studies
using this system (Emerich et al., 2019; Eyjolfsdottir et al., 2016; Fal-
cicchia et al., 2018; Fjord-Larsen et al., 2010, 2012a; Hadaczek, John-
ston, Forsayeth, & Bankiewicz, 2010; Nanobashvili et al., 2019; Paolone
et al., 2019; Wahlberg et al., 2012) we evaluated the long-term function
and neurological benefits of an encapsulated clonal human cell line based
on ARPE-19 when implanted into the brains of intact and parkinsonian
rats and minipigs. Results indicated: (1) a widespread striatal delivery of
GDNF and enhanced dopaminergic function in both rats andminipigs, (2)
high and consistent (6 months) increases in striatal levels of GDNF, (3)
that GDNF protected dopaminergic neurons when delivered prior to
6-OHDA lesions, and (4) that GDNF implants produced a significanten, RI, 02885, USA. Q2
April 2020
he CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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132improvement in neurological performance over a 62 week test period in
rats with pre-existing 6-OHDA lesions (i.e. a neurorecovery effect). The
demonstrations of long-term, controlled, and targeted delivery of GDNF
provide ongoing support for continued development of this approach as a
potential treatment for PD. In addition, this cell based technology allows
for relatively rapid clinical evaluation as the regulatory framework, GMP
manufacturing, and stereotactic instrumentation have already been
addressed in the testing of devices secreting nerve growth factor (NGF)
for the treatment of Alzheimer's patients (Wahlberg et al., 2012).
2. Methods and materials
2.1. Subjects
Adult male Sprague–Dawley rats (Harlan labs), ~3 months old and
weighing 225–250 g, were housed in groups of 4 in a temperature- and
humidity-controlled colony room that was maintained on a 12 h light/
dark cycle. Food and water were available ad libitum throughout the
experiment. Female G€ottingen Minipigs (Marshall Bioresources)
approximately 3-6 months old and weighing approximately 10–15 kg
were group housed. Animals were routinely fed Purina 5081 Mini Pig
Pellets supplemented with treats including fresh fruit/produce. Food and
water were available ad libitum throughout the experiment with the
exception of food for 12 h prior to surgery. During the study, minipigs
were routinely weighed once per week. Daily notes were taken by animal
care facility staff regarding food consumption and health status. All an-
imals were evaluated for behavior and health status by a board-certified
veterinarian prior to study initiation and once monthly during the 3
months study period. All experimentation was conducted in accord with
National Institutes of Health guidelines.
2.2. GDNF device production
ARPE-19 cells were cultured and modified to secrete GDNF as pre-
viously described (Fjord-Larsen et al., 2012a; Hadaczek et al., 2010;
Kishima et al., 2004; Nanobashvili et al., 2019; Paolone et al., 2019).
Cells were maintained using standard plating and passaging procedures
in T-175 flasks with growth medium, DMEM þ glutamax (1x) supple-
mented with 10% fetal bovine serum (Gibco). Cells were incubated at 37
C, 90% humidity and 5% CO2. And passaged every 2–3 days.
Cells were encapsulated into hollow fiber membranes as previously
described (Fjord-Larsen et al., 2012a; Hadaczek et al., 2010; Kishima
et al., 2004; Nanobashvili et al., 2019; Paolone et al., 2019). For rodent
implants, devices were manufactured from 7 mm segments of poly-
ethersulfone membrane and loaded with cells at a density of 10,000
cells/μl using a custom manufactured automated cell-loading system. For
minipig implants, 18mm long devices were producedwith a polyurethane
tether attached via a titanium linker. Devices were kept in HE-SFM at 37
C and 5% CO2 for 2–3 weeks prior to surgical implantation.
2.3. Surgical implantation of encapsulated cells
Rats were anesthetized with isoflurane (1–2%) and placed into a
stereotaxic instrument (Stoelting, inc). A midline incision was made in
the scalp, and a hole was drilled for the placement of a device into the
striatum using a stainless-steel cannula mounted to the stereotaxic frame.
The coordinates for implantation with respect to Bregma were: AP: 0.5,
ML: 3.0, and DV: 7.5.
Based on MRI-derived coordinates, minipigs were implanted with
devices into the right putamen. The animal's head was fixed during
surgery by a custom stereotactic device and continuously anesthetized
via intubation and isoflurane (1–2%) administration. A craniotomy (1.5
cm  1.5 cm) was made over the implant site and the dura was retracted
exposing the cortical surface for placement of 2 cell-loaded polymer
capsules centered in the putamen and separated by 5 mm. The capsules
were stereotactically implanted using a cannula system attached to the2stereotactic frame. At the conclusion of the surgical procedure, the tether
was cut at the cortical surface and the dura, muscle, and skin were su-
tured using routine procedures.
2.4. 6-OHDA lesion
Two striatal sites (left striatum only) were injected with 10 μg 6-
OHDA/site using a 28-gauge Hamilton syringe mounted to the stereo-
taxic frame at the following coordinates with respect to Bregma: (1) AP:
1.2, ML: 2.5, DV: 5.0 and (2) AP: 0.2, ML: 3.8, DV: 5.0. Two μl 6-
OHDA per site was infused over 2 min. The cannula was left in place for
an additional 2 min allowing the 6-OHDA to diffuse.
2.5. GDNF ELISA
A commercially available GDNF ELISA kit (DuoSet® for human GDNF
R&D Systems, Minneapolis, MN) was used to quantify GDNF device
secretion prior to implantation and again following retrieval from the
brain. Immediately following retrieval from the brain devices were
incubated at 37 C in HE-SFM. Media samples (4 h incubation) were
collected to quantify GDNF. Supernatants from pulverized and centri-
fuged tissue samples were assessed for GDNF levels using the same ELISA.
2.6. Initial in vivo clonal screening/selection
The in vivo viability and continued GDNF secretion of 3 cell clones
was evaluated to permit selection of a single clone for subsequent studies.
Cells were encapsulated and implanted into intact rat striatum as
described above. Devices were explanted 4 and 8 weeks later and GDNF
secretion and cell viability were confirmed. Twenty four rats were
randomly assigned to one of 6 treatment groups: 1–2) cell line clone-125
explanted after 4 or 8 weeks in vivo, 3–4) cell line clone-120 explanted
after 4 or 8 weeks in vivo, 5–6) cell line clone-20 explanted after 4 or 8
weeks in vivo. Groups consisted of 4 animals each with bilateral implants
providing a total of 8 explanted devices per group/time-point.
2.7. Long-term encapsulated cell function and tissue levels of GDNF in rats
Devices were implanted as described above. Devices (6–10/group)
were then removed by placing the animal into the stereotactic frame,
visualizing the proximal tip of the implant and gently removing it using
microforceps. Devices were removed at 1 day, 3 days, 1 week, 2 weeks,
and monthly from 1 to 6 months post implant and were immediately
incubated at 37 C in HE-SFM prior to processing for GDNF de-
terminations. Immediately after device removal, the previously implan-
ted striatum and overlying cortex were dissected free, placed in 1 ml of
Tissue Protein Extraction Reagent (T-PER; Thermo Scientific, Rockford,
Il) and flash frozen in liquid nitrogen. Supernatants from pulverized, and
centrifuged tissue samples were assessed for GDNF levels.
2.8. Encapsulated cell function in intact versus 6-OHDA-lesioned striatum
A second study directly compared GDNF section from devices
implanted into intact versus 6-OHDA-lesioned striatum. Animals
received unilateral 6-OHDA lesions as described above. One month later,
GDNF-secreting devices were bilaterally implanted into the striatum.
Devices were retrieved at 2 (n ¼ 6), 4 (n ¼ 6), and 8 (n ¼ 5) weeks later
and GDNF levels were determined by ELISA.
2.9. Neuroprotection studies
Rats received unilateral striatal implants of cell-loaded devices fol-
lowed 1 week later by infusion of 6-OHDA into the striatum adjacent to
the implant. All animals were weighed and tested for neurological
function prior to implantation and again at 2 and 4 weeks post lesion
using the behavioral tests outlined below. At the conclusion of testing,
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132animals were sacrificed and the brain processed for quantitative de-
terminations of the ability of GDNF to protect lesioned dopaminergic
neurons in the substantia nigra (see below for details). Sections
throughout the striatum were processed for visualization of GDNF and
tyrosine hydroxylase (TH) as described below. Three experimental
groups were used: 1): 6-OHDA alone (n¼ 8); 2): 6-OHDAþ empty device
implants (n ¼ 8); and 3): 6-OHDA þ GDNF devices (n ¼ 8).
2.10. Neurorecovery studies
Rats received unilateral intrastriatal injections of 6-OHDA followed, 1
month later, by implantation of encapsulated cells. Animals were tested
for neurological function at 4, 8, 14, 20, 30, 40, 52, and 62 weeks
following device implantation. Animals received: (1) 6-OHDA alone (n¼
8); (2) 6-OHDA þ empty device implants (n ¼ 8); and (3) 6-OHDA þ
GDNF devices (n ¼ 8).
2.11. Neurological evaluation
Using a previously published battery of tests (Emerich et al., 2019;
Nanobashvili et al., 2019; Tornøe et al., 2012), rats were evaluated to
provide a behavioral measure of the extent of the lesion as well the
magnitude of benefit provided by the GDNF implants. All tests were
conducted 24 h prior to device implantation, 24 h prior to 6-OHDA in-
jection, and again at the testing points outlined above for both the neu-
roprotection studies and the neurorecovery studies. All testing was
performed in a dim light testing room and the individual tests included
(in order of testing): the cylinder test of spontaneous forelimb use, the
spontaneous forelimb placing use and the stepping test.
2.12. Histology and immunocytochemistry
Rats were deeply anesthetized and transcardially perfused with 200
mls of 0.9% ice-cold saline. Following saline perfusion, the rats were
decapitated and the devices were removed. The brains were placed into
Zamboni's fixative for 1 week and then transferred to 25% sucrose for 48
h. Brains were then treated overnight with 20% glycerol and 2% dime-
thylsulfoxide to prevent freeze-artifacts, and multiply embedded in a
gelatin matrix using MultiBrain™ Technology (Neuroscience Associates,
Knoxville, TN). The brains were cryo-sectioned coronally at 40 micron
intervals. Every 6th section was processed for GDNF immunohisto-
chemistry using a commercially-available antibody to human GDNF
(1:1000; R&D systems). A separate series of adjacent sections was pro-
cessed for the visualization of dopaminergic terminals within the stria-
tum using TH immunocytochemistry (1:6000; Pel Freez). Additional TH-
stained sections were taken throughout the substantia nigra to visualize
and quantify the number of remaining dopaminergic neurons. A series of
sections encompassing the rostral tip of the substantia nigra pars com-
pacta to the caudal end of the substantia nigra pars reticulata was used
for manually counting of TH-positive neurons on both the lesioned and
control sides of the brain. Optical densitometry of TH-positive fibers in
the striatumwas performed on a series of 3 equally-spaced sections based
on images captured using a Nikon E800 microscope coupled to a com-
puter assisted morphometric system (iVision image analysis software;
BioVision Technologies v 4.0.10, Exton, PA).
Pigs were anesthetized and the previous surgical site exposed to
remove the implanted devices 12 weeks following implantation.
Following device removal, the pigs were transcardially perfused with 2 L
of 0.9% saline followed by 2 L of Zamboni's fixative. Brains were
removed and immersion fixed for approximately 1 week in Zamboni's
fixative prior to being transferred to 25% sucrose for 48 h. The brains
were cryo-sectioned horizontally at 40 micron intervals. Every 6th sec-
tion was saved and processed for GDNF immunohistochemistry using a
commercially-available antibody to human GDNF (1:500; R&D systems).
A separate series of adjacent sections was processed for the visualization
of dopaminergic terminals within the striatum using TH3immunocytochemistry (1:500; Pel Freez). Optical densitometry of TH-
positive fibers in the striatum was performed on a series of 5 equally-
spaced sections using NIH Image J software (v1.3 NIH).
2.13. Serum and CSF measurements
Samples of whole blood, serum, and CSF were taken from minipigs at
implant and explant (3 months). These samples were sent to Idexx Lab-
oratories (North Grafton, MA) to be analyzed for: complete blood count
(CBC) with differential, liver and kidney profile, electrolytes and serum
chemistries. The CSF was analyzed for total protein, cell count, glucose,
phosphate, potassium, chloride and calcium. Samples were also analyzed
for GDNF by ELISA.
2.14. Serum antibodies to human GDNF
The development of potential anti-GDNF antibodies was determined
with a competitive ELISA specific for pig antibodies directed against
human GDNF. Serum samples were incubated in 96 well plates coated
with human GDNF. After washing, a biotinylated anti-human GDNF
antibody was added and the amount of biotinylated antibody binding
was measured after the addition of streptavidin-HRP conjugate and TMB
substrate. The data was expressed as a ratio of sample optical density/pig
serum optical density. A ratio of less than 0.70 was considered positive
for specific human GDNF antibodies.
2.15. Statistical methods
Mixed-design ANOVAs were used to determine the effects of treat-
ment, time, and any treatment  time interactions. Where applicable,
post-hoc comparisons were conducted using t-test and Fisher's LSD test.
Statistical analyses were performed using SPSS software. In cases of
violation of sphericity assumption, Huyhn-Feldt correct F values are re-
ported. Alpha was set at 0.05 and exact p values are reported for signif-
icant results (Schallert, 2006). Mean values and standard errors of the
mean (SEM) were calculated for each group and expressed as percentage
of the intact hemisphere to facilitate graphical comparisons.
3. Results
3.1. GDNF secretion from selected cell clones
Prior to implantation, devices containing each of the 3 experimental
clones were assessed for GDNF output. As shown in Fig. 1a, these levels
ranged from approximately 200-400 ng/device/24 h (Clone-20: 411.13
 17.66; Clone-120: 224.19  11.52; Clone-125: 399.17  24.01) with
GDNF-125 devices showing the highest consistency and overall output.
After 4 weeks, GDNF levels in all clones were maintained with no
appreciable decrease relative to pre-implant values (Clone-20: 401.46 
107.78; Clone-120: 383.34 161.34; Clone-125: 407.64 87.22). At the
8 week time point, both GDNF-20 and GDNF-120 showed a reduction in
GDNF output by approximately 4-fold (Clone-20: 115.53 24.74; Clone-
120: 119.87  16.56), while GDNF-125 devices increased in output by
50% (Clone-125: 607.53  84.26). The results were confirmed by the
statistical comparison (Clone-20 V Clone-125: t (7)¼5.50, p ¼ 0.0005;
Clone-120 V Clone-125: t (7) ¼ 5.38, p ¼ 0.0001).
Based on the continued secretion of GDNF, clone-125 containing
devices were analyzed to confirm cell viability. Explanted devices were
fixed in formalin, embedded in Historesin, sectioned longitudinally and
the viability, based on morphology, was confirmed on hematoxylin eosin
(H&E)-stained sections. Histologically, GDNF-125 devices maintained
high levels of cell density after 4 and 8 weeks of implantation (Fig. 1c).
After 8 weeks in vivo, GDNF-125 devices showed no obvious signs of
declining viability, with very few pyknotic nuclei, and with the majority
of encapsulated cells maintaining a normal cytoplasmic volume and
healthy overall appearance.
Fig. 1. (a) ELISA analysis of encapsulated clonal ARPE-19 cell lines demonstrates robust continued secretion of GDNF from clone-125. While GDNF secretion from
clones 20 and 120 decreased between 4 and 8 weeks, secretion from clone-125 remained stable and even rose during the same period in vivo. (b) Immunohisto-
chemistry of tissue sections at 8 weeks post implant confirms robust diffusion of GDNF from encapsulated clone-125 cells throughput the implanted striatum and
overlying cortex. Scale bar, 500 μm in panel b and 75 μm in panel c. H&E staining on longitudinal sections of devices confirms excellent viability of encapsulated clone
125 cells. Clone-125 was used for all subsequent studies. Data are expressed as mean  SEM of 4 animals each with bilateral implants per group/time-point.
***p<0.0001; Student's t test for unpaired data.
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124Immunohistochemical staining of GDNF secreted from clone-125 cells
revealed robust distribution of the growth factor. Intense GDNF immu-
noreactivity was seen throughout the striatum and into the globus pal-
lidus and ventral pallidum. Immunoreactivity was also observed in the
corpus callosum and the overlying cortex adjacent to the implant site
(Fig. 1b). Areas outside of the immediate site were completely devoid of
GDNF immunoreactivity confirming the specificity of the staining. While
not examined here, our previous studies have confirmed that these high
levels of GDNF secretion are not associatedwith any alteration in reactive
gliosis around the implant site (Falcicchia et al., 2018; Nanobashvili
et al., 2019; Paolone et al., 2019).125
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1323.2. Long-term secretion and tissue distribution of GDNF
Quantitation of device output illustrated a continued and stable
secretion of GDNF from the implanted devices. Prior to implantation,
devices secreted approximately 480 ng/day (484.99  31.29) of GDNF.
Explanted devices showed an initial increase in secretion peaking at
approximately 3–14 days (1095.15  42.17) and then tapering to a4sustained level that remained at pre-implant levels for the 6-month in
vivo period (Fig. 2a; 312.31 65.33). The continued delivery of GDNF to
the striatum significantly elevated tissue concentrations of GDNF as
determined by ELISA. Of note, as reported in previously published
studies (Falcicchia et al., 2018; Hadaczek et al., 2010; Paolone et al.,
2019), we removed and analyzed the entire implanted striatum. This
allowed us to gain insight into tissue concentrations of GDNF in the target
striatum as opposed to using a protein-based average or highly variable,
smaller tissue punches. Accordingly, the final data are expressed as ng of
GDNF in the whole striatum. Tissue concentrations of GDNF were
elevated within 1 week following implantation, reaching peak levels at
approximately 2 weeks (17.21  1.53) and then plateauing thereafter to
remain relatively constant for at least 6 months post implantation
(Fig. 2b).3.3. Encapsulated cell function in intact versus 6-OHDA-lesioned striatum
Levels of GDNF secretion from explanted devices at 2–8 weeks post
implantation are reported in Table 1. Prior lesioning of the dopaminergic
Fig. 2. Long-term, sustained delivery of GDNF and resulting elevation tissue
levels of GDNF within the implanted striatum. Fig. 2a demonstrates that GDNF
device secretion peaks early post implantation but then stabilizes and remains
consistent for at least 6 months in vivo. Fig. 2b confirms that GDNF delivery
results in sustained tissue levels within the implanted striatum. When explanted
from the striatum the output of the devices over time generally paralleled the
enhanced tissue concentrations with an early peak in delivery followed by a
longer, sustained output similar to that noted from the same devices immedi-
ately prior to implantation. All data are expressed as mean  SEM of 4 animals
each with bilateral implants per time-point. BLQ ¼ below limit of quantitation.
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109innervation of the striatum with 6-OHDA, did not impact GDNF output
from devices explanted at 2–8 weeks post implantation (Table 1).110
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1223.4. Neuroprotection study
All animals recovered rapidly from surgery. Cage-side observations
were performed daily and body weights were recorded periodically prior
to surgery and during the 4 week testing period. No overt signs of
behavioral toxicity were observed in any animal at any time. Likewise, no
alterations in body weights were noted in treated animals relative to
controls. Subsequent weight gain was rapid and comparable in all groups
following 6-OHDA lesions. Before implantation and after retrieval, the
encapsulated cells were assayed for GDNF secretion by ELISA. Before
implantation, the encapsulated cells released 578.62  28.95 ng GDNF/Table 1
GDNF secretion from encapsulated cells implanted into intact versus 6-
OHDALesioned.
Intact Striatum 6-OHDA- Lesion
Pre-Implant 144.21 (8.14) 147.69 (8.91)
2 Weeks 298.83 (129.15) 323.86 (84.98)
4 Weeks 552.25 (142.91) 564.27 (152.43)
8 Weeks 393.76 (56.82) 378.33 (84.49)
Data are expressed as mean  SEM ng GDNF/24 h.
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5capsule/24 h. Post-explant values of GDNF from capsules explanted after
5 weeks in vivo averaged 507.59  11.44 ng GDNF/capsule/24 h. GDNF
was undetectable in media incubated with explanted empty capsules.
Quantification of TH-positive neurons in the substantia nigra (Fig. 3a)
revealed that the animals in the lesion only group had an extensive loss of
TH-positive neurons (decreased 65% relative to the intact, contralateral
side) at 4 weeks post lesion (Fig. 3b; 6-OHDA: 35.51  3.01). A similar
loss of TH-positive neurons (6-OHDA þ empty: 28.41  3.46; decreased
72%) was observed in lesioned animals receiving an empty device. In
contrast, animals receiving GDNF implants exhibited a marked sparing of
TH-positive neurons with only a 6% loss of neurons observed (6-OHDAþ
GDNF: 94.06  5.12; F(2,21) ¼ 82.36, p<0.001). Accompanying the loss
of TH-positive neurons in the control groups was an extensive loss of TH-
positive fibers in the striatum that was previously injected with 6-OHDA.
The preservation of dopaminergic neurons in the GDNF-treated rats was
associated with a notable preservation of TH-positive terminals in the
striatum (Fig. 4a). Quantitative optical density measurements of TH fiber
density confirmed these observations as the control animals (lesion only:
30.55  5.35; and lesion þ empty devices: 19.94  5.10) displayed
70–80% reductions in TH fiber density while those animals receiving
GDNF displayed a more modest 33% reduction of TH-positive fiber
density (Fig. 4b; 6-OHDA þ GDNF: 67.16  3.77; (F(2,21) ¼ 39.16;
p<0.001).
Tests of forelimb function in the cylinder, placing, and stepping tests
confirmed that all groups of rats displayed normal forelimb use prior to
the initiation of the study (pre-implant; Fig. 5). A modest decrease in
body weight was observed following surgical implantation but this effect
was not different from control animals that received sham surgery.
However, no treatment related changes in body weights were noted over
test period (Fig. 5a). Implantation of either empty devices or GDNF de-
vices did not impact performance on any of the behavioral tasks. In
contrast, the 6-OHDA lesion produced significant and comparable
behavioral deficits in both the lesion only and lesion þ empty device
groups. This effect was consistent, did not vary when the animals were
tested at 2 versus 4 weeks post-lesion and confirmed by the significant
time treatment interaction (Touches: F(6,63)¼ 13.68, p< 0.001; Places:
F(6,63)¼ 78.97, p< .001; Steps: F(6,63) ¼ 10.82, p< .001). Relative to the
intact forelimb, performance on the contralateral and impaired forelimb
was decreased 45–58%, 67%–72%, and 65%–70% in these control
groups on the cylinder (Fig. 5b), placing (Fig. 5c), and stepping (Fig. 5d)
tests, respectively. In contrast, the GDNF treated rats displayed virtually
normal performance and the results were confirmed by a main effect of
treatment (Touches: F(2,21) ¼ 43.75, p < 0.001; Places: F(2,21) ¼ 201.21,
p < 0.001; Steps: F(2,21) ¼ 7.26, p ¼ 0.004). These neurological tests also
confirmed the potent protection afforded by the GDNF implants. Use of
the contralateral forelimb in the cylinder and placing tests was decreased
10–12% relative to the intact limb but this effect was not significant and
did not differ from pre-implant performance. These benefits were also
observed in the stepping test. Although a trend towards a deficit was seen
in the GDNF-treated animals at 4 weeks post lesion, this effect did not
reach statistical significance (Fig. 5d; p<0.10).
3.5. Neurorecovery
The studies evaluated the ability of cell-based GDNF, to promote
neurological recovery following loss of dopaminergic neurons. Consistent
with the neuroprotection studies, 6-OHDA produced clear and consistent
deficits in performance on the cylinder, placing, and stepping tests
(Fig. 6). Modest improvements in performance were noted on the cyl-
inder and placing tests as early as 4 weeks post implantation although
these effects did not achieve statistical significance. However, these small
benefits continued to gradually grow in magnitude and confirmed by the
significant time  treatment interaction (Touches: F(18,189) ¼ 4.22, p <
0.001; Places: F(18,189) ¼ 4.46) at 8 weeks (17–19% improvement) and
peaking at 62 weeks post treatment (i.e, the latest time-point examined)
when the improvement was >70% relative to controls. While these
Fig. 3. Photomicrographs of substantia
stained for TH immunoreactivity illustrating
loss of dopaminergic neurons following 6-
OHDA and preservation of those neurons
following GDNF treatment (a). Quantitation
of dopaminergic neurons in the substantia
nigra demonstrates virtually complete pro-
tection of lesioned neurons (b). Data are
presented as mean  SEM % of TH-positive
neurons relative to the intact, non-lesioned
hemisphere of 8 animals per group. Scale
bars, 200 μm. Multiple comparisons were
based on significant main effects of treatment
resulting from the ANOVA described in Re-
sults: **p<0.01.
Fig. 4. Photomicrographs of striatum stained for TH immunoreactivity (a) and quantitation of TH fiber density (b) following 6-OHDA with and without GDNF
treatment illustrates a robust ability of GDNF to preserve dopaminergic fibers. Scale bars ¼ 500 μm Data are presented as mean  SEM % of TH-positive fibers relative
to the intact, non-lesioned hemisphere of 8 animals per group. Multiple comparisons were based on significant main effects of treatment resulting from the ANOVA
described in Results: **p<0.01.
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132benefits were robust and consistent on the cylinder (main effect of
treatment: F(2,21) ¼ 37.17, p < 0.001) and placing tests (main effect of
treatment: F(2,21) ¼ 61.41, p < 0.001), no changes were observed on the6stepping test (data not shown) in treated animals. No treatment related
changes in body weights were noted over the 62 week test period
(Fig. 6a).
Fig. 5. Normal weight gain and neurological performance is maintained in lesioned animals by implantation of GDNF devices. (a) Body weights of animals with and
without GDNF treatment. (b–d) Performance in the cylinder, placing, and stepping tests are all significantly impaired at 2 and 4 weeks following intrastriatal injections
of 6-OHDA. In contrast, performance on each of these tests is preserved by GNDF implants with treated animals performing comparably to pre-surgery levels (pre-
implantation and pre-lesion). Data are presented as mean  SEM of 8 animals per group. Multiple comparisons were based on significant main effects or interactions
resulting from ANOVAs that are described in Results: **p<0.01.
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132At the conclusion of the long-term study (62 weeks) the devices were
retrieved, the brains processed and stained for GDNF and TH. All devices
were easily retrieved intact without any evidence of adherent tissue. The
GDNF output of the devices prior to implant was approximately 345 ng/
day. At explant, GDNF output remained high at approximately 222 ng/
day. The continued secretion of GDNF was paralleled by a robust and
striatal-wide diffusion of GDNF (Fig. 7a). GDNF was visible throughout
the implanted striatum as well as the overlying cortex which the implant
extended through. Paralleling the robust neurological recovery and
diffusion of GDNF throughout the striatum was a significant enhance-
ment of striatal TH-positive fibers. While control animals exhibited a
marked loss of dopaminergic fibers post 6-OHDA (Fig. 7b), animals
treated with GDNF exhibited a dense TH fiber network surrounding the
implant site and extending throughout the implanted striatum (Fig. 7c).
3.6. GDNF distribution from clinical-sized devices in minipig brain
Following implantation, all animals recovered rapidly post-surgery
and demonstrated normal activity and feeding behavior within several
hours post-recovery. The formal monthly health status assessments
confirmed the normal behavior of all animals at all times during the
study. Food consumption was normal throughout the study and the pigs
gained weight at a rate that would be anticipated by previously published
guidelines provided by the vendor.
All devices were easily retrieved intact without any notable tissue
adherence. Data from the 3 month test subjects demonstrated that all7devices continued to secrete high levels of GDNF (Fig. 8b). Over the 3
month test period GDNF output increased by 51%. Immunohistochem-
istry confirmed that the secreted GDNF was widely distributed
throughout the implanted striatum (Fig. 8a and b; pre-implant: 1206.33
 142.38; post-explant: 1817.42  308.17; t (5) ¼ 1.18, p ¼ 0.021). As
shown below in Fig. 8c and d, the diffusion of GDNF throughout the
striatum from 2 devices robustly upregulated TH staining in the region of
GDNF distribution. Quantitative determinations of the optical density of
TH in the putamen and caudate confirmed the apparent upregulation of
TH as the relative optical density of TH staining was increased by 48% in
the treated striatum versus the non-implanted, control striatum (Intact:
34.11  3.61; GDNF: 48.69  4.97; t (5) ¼ 5.13, p ¼ 0.004).
3.7. Serum and CSF measurements
To assess the systemic safety and tolerability of GDNF, standard
clinical chemistry and hematology was performed at baseline and again
at explant 3 months later. In all pigs, the values for serum chemistry and
blood counts at explant did not deviate from baseline ranges. Likewise,
no changes were noted when the CSF was analyzed for total protein, cell
count, glucose, phosphate, potassium, chloride and calcium (data not
shown).
GDNF levels were quantified in serum and CSF using an ELISA specific
for human GDNF that was validated for porcine serum and CSF matrices.
GDNF was not detected in serum or CSF at baseline in any animal. In
contrast, GDNF was detectable in serum, but not quantifiable, at 3
Fig. 6. Long-term, normal weight gain (a) and neurological performance in rats
receiving GDNF implants 1 month post 6-OHDA. Then evaluated for 62 weeks.
Testing on both the cylinder and placing tests (b-c) revealed a smooth and ever
growing improvement in performance over the 62 week testing period. Data are
presented as mean  SEM of 8 animals per group. Multiple comparisons were
based on significant main effects or interactions resulting from ANOVAs that are
described in Results: *p<0.05.
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123months in 4 out of 6 GDNF-treated animals (Table 2). CSF levels of GDNF
were detectable and quantifiable in 5 out of 6 GDNF-treated pigs with
levels ranging from 187 to 1001 pg/ml.124
125
126
127
128
129
1303.8. Serum antibodies to human GDNF
Serum samples were collected at implant and at explant (3 months).
Using a competitive ELISA to detect the presence of anti-GDNF anti-
bodies, these analyses confirmed that the serum samples from all pigs8were negative for anti-GDNF antibodies.
4. Discussion
While treating PD with pharmacologics such as levodopa and dopa-
minergic agonists provides temporary symptomatic relief of the motor
symptoms, the progressive loss of dopaminergic neurons eventually
renders these drugs ineffective and continued use results in side effects
such as drug-induced dyskinesias (Fahn et al., 2004; Kucinski, Paolone,
Bradshaw, Albin,& Sarter, 2013; Paolone, Brugnoli, Arcuri, Mercatelli,&
Morari, 2015). Trophic factors have been suggested to be a more optimal
potential treatment to both restore the function of dopaminergic neurons
while also protecting them from further damage and loss. In this regard,
GDNF is a potent factor known to restore and augment nigrostriatal
dopaminergic function in rodent and non-human primate models of PD
(Dowd et al., 2005; Gash et al., 1996; Grondin et al., 2003; Kordower
et al., 2000; Miyoshi et al., 1997; Palfi et al., 2002; Wang et al., 2002;
Zheng et al., 2005).
Clinical evaluation of GDNF in PD patients has been promising but
inconsistent, potentially because of insufficient distribution of GDNF
throughout the nigrostriatal system. Several strategies are under devel-
opment to optimize the diffusion and spread of trophic factors into brain
tissue including direct brain infusion (Morrison, Lonser,&Oldfield, 2007),
gene therapy approaches (Kordower et al., 2000; Palfi et al., 2002) and
cell-based delivery using stem cells (Fjord-Larsen et al., 2012b; Gasmi et al.,
2007; Shi et al., 2011). Here we describe the development of a delivery
system based on implanting trophic factor-secreting cells that have been
encapsulated inside of a polymer membrane. The pores of the membrane
allow GDNF to cross the membrane into the surrounding brain tissue
while protecting the encapsulated cells from host immune destruction.
Previous iterations of this general technological approach were generally
supportive of the notion but lacked the high-level section and long-term
time duration shown here (16–18). These novel data demonstrate, an
implantable and removable encapsulated cellular device capable of
providing high levels of human native and glycosylated GDNF suitable
for dopaminergic neuroprotection and restoration (Hadaczek et al.,
2010; Nanobashvili et al., 2019; Paolone et al., 2019). The long-term (at
least 6 months) targeted delivery of GDNF over the majority of the
nigrostriatal system without host-cell modification makes the system
attractive for clinical translation in patients with Parkinson's disease.
Even with significantly enhanced secretion of factors such as GDNF,
multiple implant sites will still likely be required to deliver enough factor
to cover the target region in a human brain. The present studies with 2
implants in minipig brain demonstrated robust delivery of GDNF
throughput the entire striatum with diffusion distances>5 mm along the
entire axis of each implant. Based on these data near complete coverage
of the human putamen could be achieved with 3–4 implants identical in
size and configuration to those used here. Multiple implants should not
pose significant surgical or safety concerns as previous regulatory
approved clinical trials have already incorporated the concurrent inser-
tion of up to 4 implants into the brains of Alzheimer's patients with a
good safety record (Wahlberg et al., 2012).
Immunohistochemistry confirmed that GDNF was distributed
throughout the striatum and that this widespread distribution resulted in
a virtually complete protection of dopaminergic neurons in the 6-OHDA-
lesioned substantia nigra and preservation of TH-positive fibers in the
striatum. These same animals demonstrated normal motor performance
when evaluated on 3 separate neurological tests (cylinder, placing, and
stepping tests). While modest residual deficits were noted on the cylinder
and stepping tests in treated animals these changes were very small (<5%
change from baseline) and did not reach statistical significance. While
the neuroprotection paradigm described in this report required relatively
short-term GDNF delivery, subsequent data provided substantial support
for the ability of encapsulated cells to promote long-term, controlled, and131
132
Fig. 8. Implantation of 2 clinical-sized devices into
the right putamen of minipigs delivers GDNF for 12
weeks and produces widespread delivery of GDNF
(a–b) throughout the implanted striatum. GDNF de-
livery is also associated with a profound biological
upregulation on dopaminergic function as determined
by enhanced TH-immunoreactivity and quantitative
optical densitometry in the striatum (c–d). Scale bars
¼ 5 mm. Data are presented as mean  SEM of 6 an-
imals. *p<0.05; **p<0.01, Student's t test.
Fig. 7. GDNF immunoreactivity in rat striatum 62 weeks following implantation of encapsulated GDNF-secreting cells (a) is associated with a pronounced preser-
vation of TH-positive fibers that normally occurs post 6-OHDA (b–c). Scale bars ¼ 500 μm.
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132functional delivery of GDNF to the nigrostriatal system. First, studies in
rats quantified the 6-month continued delivery of GDNF to the striatum.
Compared to pre-implant levels, GDNF secretion from explanted devices
initially increased for the first couple of weeks and then stabilized at
approximately pre-implant levels for the remaining 6 months. Second,9the release of GDNF from the encapsulated cells resulted in robust ele-
vations of GDNF in the tissue surrounding the implant site. Again, GDNF
levels in tissue initially peaked early but then settled into a long (6
months) and stable elevation within the implanted striatum. Third, GDNF
delivery from encapsulated cells promoted neurological recovery in the
58
4
Table 2
Serum and CSF measurements following GDNF implants in minipig Brain.
Pig ID # Anti-GDNF Serum Antibodies CSF GDNF (pg/ml) Serum GDNF (pg/ml)
IMPLANT EXPLANT IMPLANT EXPLANT IMPLANT EXPLANT
1805 NEG NEG BLQ BLQ/DET BLQ BLQ
1902 NEG NEG BLQ 187 BLQ BLQ/DET
8936 NEG NEG BLQ 554 BLQ BLQ/DET
1406 NEG NEG BLQ 249 BLQ BLQ
1538 NEG NEG BLQ 1335 BLQ BLQ/DET
2330 NEG NEG BLQ 1001 BLQ BLQ/DET
BLQ: Below the Limit of Quantitation (94 pg/ml of serum and 64 pg/ml of CSF).
BLQ/DET: Below the Limit of Quantitation but Detectable.
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132already lesioned nigrostriatal system (i.e; a neurorecovery/restorative
model). When rats received implants post 6-OHDA a slow, steady
improvement was noted in both the cylinder and placing tests. This
improvement started within 1–2 months and continued to gain mo-
mentum over the 62 week test period. The observation of long-term (at
least 62 weeks) GDNF immunoreactivity throughout the rodent striatum
together with a marked recovery in TH-positive fiber density in the
previously denervated striatum suggest that at least some of the motor
recovery is accounted for by sprouting or regeneration of post-lesion,
residual dopaminergic terminals. Follow up studies will be required to
precisely correlate the timing of GDNF delivery to neurochemical and/or
anatomical changes that contribute to neurological recovery. Nonethe-
less, the combined neuroprotective and neurorestorative actions
described here suggest the potential of encapsulated cell-based GDNF
delivery to provide a potent first in class disease modifying therapy.
5. Conclusion
These results describe the use of polymer-encapsulated GDNF-
secreting cells for direct and local delivery of GDNF to the brain, in hopes
of developing a treatment for PD patients. These studies demonstrated
long-term and stable bioactive/efficacious effects on the nigrostriatal
dopaminergic system. As such, this delivery system represents a novel
version of previous encapsulated cell-based systems to deliver trophic
factors to the brain and may be developed into a disease modifying and
effective treatment for PD and other diseases (Emerich et al., 2019;
Falcicchia et al., 2018; Nanobashvili et al., 2019; Orive, Echave,
Dolatshahi-Pirouz, Paolone, & Emerich, 2019; Paolone et al., 2019; Saito
et al., 2017; Tornøe et al., 2012).
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